Last reviewed · How we verify
ALRN-6924 in combination with cytarabine — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ALRN-6924 in combination with cytarabine (ALRN-6924 in combination with cytarabine) — Aileron Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ALRN-6924 in combination with cytarabine TARGET | ALRN-6924 in combination with cytarabine | Aileron Therapeutics, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ALRN-6924 in combination with cytarabine CI watch — RSS
- ALRN-6924 in combination with cytarabine CI watch — Atom
- ALRN-6924 in combination with cytarabine CI watch — JSON
- ALRN-6924 in combination with cytarabine alone — RSS
Cite this brief
Drug Landscape (2026). ALRN-6924 in combination with cytarabine — Competitive Intelligence Brief. https://druglandscape.com/ci/alrn-6924-in-combination-with-cytarabine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab